In breast cancer, a deletion polymorphism that generates an APOBEC3A/B chimera is associated with increased disease risk, more APOBEC3-induced mutations, and poor tumor differentiation (a sign of negative prognosis) [47, 61, 62, 64, 104, 105]. Here, APOBEC3A is linked to neoplasm.